MaxCyte, Inc. Signing of Strategic Platform License (5268F)
July 10 2023 - 8:05AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 5268F
MaxCyte, Inc.
10 July 2023
MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform
License to
Advance Next Generation Cellular Therapies
MaxCyte's Flow Electroporation(R) technology and ExPERT(TM)
platform will support Vittoria's Senza5(TM) technology to enhance
efficacy and improve clinical utility of T cell therapies.
ROCKVILLE, MD, and PHILADELPHIA, PA July 10, 2023 - MaxCyte,
Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering
focused company providing enabling platform technologies to advance
the discovery, development and commercialization of next-generation
cell-based therapeutics and to support innovative, cell-based
research, and Vittoria Biotherapeutics (Vittoria), a leading edge,
gene-edited cell therapeutics company with novel platform
technologies poised to develop a pipeline of highly differentiated
cellular therapies for both oncology and immunology indications,
today announced the signing of a strategic platform license (SPL)
of MaxCyte's Flow Electroporation(R) technology and ExPERT(TM)
platform to Vittoria Biotherapeutics.
Under the terms of the agreement, Vittoria will obtain
non-exclusive clinical and commercial rights to use MaxCyte's Flow
Electroporation(R) technology and ExPERT(TM) platform. In return,
MaxCyte is entitled to receive platform licensing fees and
program-related revenue.
Vittoria's technology and clinical programs are designed to
address current gaps with contemporary cell therapies and the
Company is planning to file an investigational new drug application
(IND) for their lead program, Viper 101, later this year. Viper 101
is a gene-edited, autologous, dual-population cell therapy
developed from Vittoria's proprietary Senza5(TM) platform that
addresses significant unmet therapeutic need for the treatment of
T-cell lymphoma. Vittoria's patent-protected Senza5(TM) platform
technology is designed to improve the viability, efficacy, and
safety of CAR-T treatments by modulating a novel checkpoint pathway
in engineered T cells. Senza5(TM) CAR-T cells have demonstrated
superior anti-tumor efficacy in both liquid and solid tumor
preclinical models and utilize a proprietary five-day manufacturing
process.
"Working with partners to produce best-in-class solutions that
accelerate the development of novel therapies to improve patient
outcomes is central to our company's mission" said Doug Doerfler,
President and Chief Executive Officer of MaxCyte. "Through our
partnership with Vittoria, MaxCyte has gained an opportunity to
further validate and showcase our technology in a real-world
setting and expand its footprint in the promising field of CAR-T
therapies. We look forward to supporting Vittoria's efforts to
improve efficacy and enhance safety of T-cell therapies."
"At Vittoria, our goal is to deliver next-generation T-cell
therapies designed to improve patient outcomes by enhancing the
overall clinical utility and safety of engineered cell therapies,"
said Nicholas Siciliano, Ph.D., Chief Executive Officer of
Vittoria. "MaxCyte's experience with clinical grade manufacturing
of gene-edited cellular therapeutics will greatly enhance the
robustness and reproducibility of our manufacturing process,
ensuring that each batch of our CAR-T cells meets the highest
standards of consistency and quality. This is an important step
forward as we work to develop the next generation of cellular
therapies to benefit patients."
MaxCyte's ExPERT(TM) instrument portfolio is the next generation
of leading, clinically validated electroporation technology for
complex and scalable cell engineering. By delivering high
transfection efficiency, seamless scalability and enhanced
functionality, the ExPERT(TM) platform delivers the high-end
performance essential to enabling the next wave of biological and
cellular therapeutics. Vittoria is MaxCyte's 22(nd) SPL
overall.
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize
the potential of cells to improve patients' lives. We have spent
more than 20 years honing our expertise by building best-in-class
platforms, perfecting the art of the transfection workflow, and
venturing beyond today's processes to innovate tomorrow's
solutions. Our ExPERT(TM) platform, which is based on our Flow
Electroporation (R) technology, has been designed to support the
rapidly expanding cell therapy market and can be utilized across
the continuum of the high-growth cell therapy sector, from
discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx(TM), STx(TM), GTx(TM)
and VLx (TM); a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio. By providing
our partners with the right technology, as well as technical and
regulatory support, we aim to guide them on their journey to
transform human health. Learn more at maxcyte.com and follow us on
Twitter and LinkedIn .
About Vittoria Biotherapeutics
Vittoria Biotherapeutics, Inc. ( https://vittoriabio.com ) is a
leading edge, gene-edited cell therapy company with novel platform
technologies exclusively licensed from the University of
Pennsylvania. Vittoria's technology and clinical programs are
designed to address current gaps with contemporary cell therapies
and its pipeline benefits from access to novel gene editing
technologies. The Company is on track to file an IND in mid-2023
for their lead program, Viper 101. Viper 101 is a gene-edited,
autologous, dual-population cell therapy that addresses a
significant unmet therapeutic need for the treatment of T-cell
lymphoma. Vittoria's gene-edited platform technology has
demonstrated superior anti-tumor efficacy in both liquid and solid
tumor preclinical models and utilizes a proprietary "short" (5-day)
manufacturing process. To learn more, visit vittoriabio.com and
follow us on LinkedIn .
MaxCyte Contacts:
US IR Adviser US Media Relations
Gilmartin Group Spectrum Seismic Collaborative
David Deuchler, CFA Valerie Enes
+1 415-937-5400 +1 408-497-8568
ir@maxcyte.com valerie@spectrumscience.com
Nominated Adviser and Joint UK IR Adviser
Corporate Broker Consilium Strategic Communications
Panmure Gordon Mary-Jane Elliott
Emma Earl / Freddy Crossley Chris Welsh
Corporate Broking +44 (0)203 709 5700
Rupert Dearden maxcyte@consilium-comms.com
+44 (0)20 7886 2500
Vittoria Contacts:
Investor Contact Media Relations
Vittoria Biotherapeutics LifeSci Communications
Nicholas A. Siciliano, Ph.D. Michael Tattory
Chief Executive Officer +1 609-802-6265
+1 215-600-1380 mtattory@lifescicomms.com
nsiciliano@vittoriabio.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGRRMMBTMTIBBBJ
(END) Dow Jones Newswires
July 10, 2023 08:05 ET (12:05 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024
